Researchers look at sildenafil use in cirrhosis patients
People diagnosed with diabetes spend over $4,100 more each year on medical costs than people who don’t have diabetes, a gap that increases substantially each year following the initial diagnosis, according to a study published online today in the journal Diabetes Care. In the first study to examine medical cost increases for individuals living with
Full Post: Study examines medical cost increases for individuals living with diabetes
Sildenafil is valuable in the treatment of erectile dysfunction and pulmonary hypertension in patients with end-stage liver disease through inhibition of the type-5 phosphodiesterase.
The type-5 phosphodiesterase is also present in human mesenteric arteries. The effect of sildenafil on splanchnic blood flow and portal hypertension remains essentially unknown.
The research team led by Otto Clemmesen from Denmark addresses this question and this will be be published on October 28; 2008 in the World Journal of Gastroenterology.
Ten patients with biopsy proven cirrhosis (5 females/5 males, mean age 54 ? 8 years) and the hepatic venous pressure gradient (HVPG) above 12 mmHg were studied after informed consent. Measurement of splanchnic blood flow and the HVPG during liver vein catheterization were done before and 80 min after oral administration of 50 mg sildenafil. Blood flow was estimated by use of indocyanine green clearance technique and Fick’s principle, with correction for non-steady state.
They found that the plasma concentration of sildenafil was 222 ? 136 ng/mL 80 min after administration. Mean arterial blood pressure decreased from 77 ? 7 to 66 ? 12 mmHg, P = 0.003, while the splanchnic blood flow and oxygen consumption remained unchanged at 1.1 ? 0.71 L/min and 2.3 ? 0.6 mmol/min, respectively. Also the HVPG remained unchanged (18 ? 2 vs 16 ? 2 mmHg) with individual changes ranging from -8 to +2 mmHg. In 7 patients HVPG decreased and in 3 it increased.
The result indicated that sildenafil do not induce any profound clinically relevant changes in splanchnic blood flow, oxygen consumption and HVPG in patients with cirrhosis. Phosphodiesterase type-5 inhibition is of no use as a therapeutic agent for alleviating portal hypertension in patients with chronic end-stage liver disease.
More than half of people diagnosed with high blood pressure do not have it under control and many more go undiagnosed, according to research carried out at the University of Warwick. Professor Franco Cappuccio from Warwick Medical School at the University of Warwick led the only UK team to participate in a European study examining
Full Post: High blood pressure a looming problem for Europe
A French study reported in the 12th January issue of Archives of Internal Medicine has found a strong correlation between blood pressure and outdoor temperature in a large sample of the elderly.(1) As a result, the investigators advise that, during periods of extreme temperatures, careful monitoring of blood pressure and antihypertensive treatment “could contribute to
Full Post: Seasonal variation in blood pressure
The name “Herbal Viagra” is applied to medications used for treatment of erectile dysfunction in men. Viagra (Sildenafil citrate) was developed by the Pfizer International Inc., a drug producing company. As of now, it has become a generic name applied to various medicines, by aid of which sexual dysfunction is treated. Many of them do
Full Post: Herbal Viagra
Continuously measuring blood pressure may help predict heart disease and related deaths among individuals with treatment-resistant hypertension, while blood pressure readings taken in a medical office do not appear to predict future heart risks, according to a report in November 24 issue of Archives of Internal Medicine. About 10 percent to 30 percent of individuals
Full Post: Blood pressure readings taken at medical office do not appear to predict future heart risks
NicOx S.A. has announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod
Full Post: NicOx’s Naproxcinod shows highly significant reduction in daytime blood pressure versus Naproxen